Sagan et al. investigated the mechanism involving the loss of tolerance in the development of demyelinating disorders mediated by AQP4 or MOG autoantibodies. Characteristically, AQP4 is expressed not only in CNS but also in other tissues otherwise MOG is restricted…
Read more
Pham MC et al. overcoming the study of polyclonal serum in patients with myasthenia gravis (MG) by producing several monoclonal antibodies (mAb) which target the nicotinic acetylcholine receptor (AchR) reporting that: The single autoreactive clones can react…
Read more
Myasthenia gravis (MG) is a prototypical neuroimmunological disorder in which autoantibodies targeting the neuromuscular junction play a key role in the pathogenesis. Granit et Al. reported the results of a prospective, multicenter, open-label, phase 1b/2a study…
Read more
Globoid cell leukodystrophy (GLD) is a fatal genetic demyelinating disorder of the central nervous system. GLS is caused by loss-of-function mutations in the galactosylceramidase (galc) gene, but several neuropathological data have suggested a relevant role…
Read more
